

DOCTORAL THESIS

Protopine and Its Derivatives Mitigate Tau Pathology Via Histone Deacetylase 6 Inhibition in Alzheimer's Disease Models

SREENIVASA MURTHY, Sravan G S

Date of Award:
2021

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

ABSTRACT

The low success rates of clinical trials for Alzheimer's Disease (AD) medicament has demanded for safer and effective novel drugs. In AD, neurofibrillary tangles (NFTs) enriched with hyperphosphorylated tau is the causative factor for memory and cognitive imbalance. Emerging evidence has demonstrated an impairment of the ubiquitin-proteasomal system (UPS) upon accumulation of hyperphosphorylated tau. Histone deacetylase 6 (HDAC6) is a vital enzyme involved in tau hyperphosphorylation and cognitive dysfunction in AD animal models. Furthermore, previous studies have shown that downregulating HDAC6 activity and enhancing carboxy-terminus of HSC70 interacting protein (CHIP) mitigates tau pathology in AD. In the current study, we have elucidated the cognition-enhancing effects and the underlying mechanisms of isoquinoline alkaloid, Protopine (PRO), isolated from traditional Chinese medicine, *Corydalis yanhusuo*. PRO specifically reduced the hyperphosphorylated tau and alleviated the learning and memory dysfunction in triple transgenic 3xTg-AD mice and mutant tau overexpressed P301S tau mice models. Molecular docking, solid-phase binding, and fluorometric assays suggested that PRO directly binds to the catalytic domain 1 (CD1) of HDAC6 and inhibits its activity. PRO enhanced the expression of molecular chaperones and CHIP E3 ubiquitin ligase *in vitro* and *in vivo*, which further promoted the degradation of ubiquitinated tau via the ubiquitin-proteasomal system (UPS).

To develop more potent HDAC6 inhibitors with optimized brain bioavailability for treating AD, a chemical derivative of PRO, termed PRO-Br, was synthesized. The physicochemical characteristics were evaluated by Nuclear magnetic resonance spectroscopy and tandem mass spectrometry. In 3xTg-AD and P301S mice models, PRO-Br specifically promoted the

degradation of sarkosyl insoluble tau. Additionally, immunohistochemical results demonstrated that PRO-Br significantly reduced the hyperphosphorylated tau in both AD model mice. The fluorometric assay showed that PRO-Br decreased HDAC6 activity in a dose-dependent manner.

Altogether, our findings demonstrated that 1) PRO-Br is a better blood-brain barrier permeable compound than PRO; 2) PRO-Br is a better inhibitor of HDAC6 activity, compared to PRO; 3) PRO and PRO-Br can enhance the expression of molecular chaperones and specifically promote the degradation of pathological hyperphosphorylated tau in 3xTg-AD as well as P301S tau AD models; 4) PRO and PRO-Br can mitigate the memory and cognitive impairment in both AD model mice; and 5) PRO and PRO-Br can be developed into potential drugs for treating AD.

Keywords: Alzheimer's disease, Phospho-tau, Protopine, PRO-Br, 3xTg-AD mice, P301S tau mice, HDAC6.

TABLE OF CONTENTS

| | |
|---|------------|
| <i>DECLARATION</i> | <i>i</i> |
| <i>ABSTRACT</i> | <i>ii</i> |
| <i>ACKNOWLEDGEMENTS</i> | <i>iv</i> |
| <i>TABLE OF CONTENTS</i> | <i>vi</i> |
| <i>LIST OF FIGURES</i> | <i>xi</i> |
| <i>LIST OF TABLES</i> | <i>xiv</i> |
| <i>LIST OF ABBREVIATIONS</i> | <i>xv</i> |
| CHAPTER 1: INTRODUCTION | 1 |
| 1.1 Neurodegenerative disease | 2 |
| 1.2 Alzheimer’s disease and Tau pathology | 2 |
| 1.2.1 Alzheimer’s disease epidemiology | 2 |
| 1.2.2 Alzheimer’s disease pathology | 3 |
| 1.2.3 Tau protein structure and pathology | 5 |
| 1.2.4 Tau degradation mechanisms | 8 |
| 1.3 Histone deacetylases (HDACs) and Tau pathology | 16 |
| 1.3.1 Classification of HDACs | 17 |
| 1.3.2 HDAC in neurodegeneration | 18 |
| 1.3.3 Drawbacks of HDAC inhibitors | 19 |
| 1.3.4 HDAC6 in Tau pathology | 20 |
| 1.4 Therapeutic strategies in Tauopathy patients | 21 |

| | | |
|---|--|-----------|
| 1.5 | The neuroprotective effects of Yuanhu Zhi Tong (YZT 元胡止痛)..... | 24 |
| 1.5.1 | Introduction to Rhizoma Corydalis | 25 |
| 1.5.2 | Introduction to Radix Angelicae Dahuricae | 32 |
| CHAPTER 2: HYPOTHESIS AND OBJECTIVES..... | | 37 |
| CHAPTER 3: RESEARCH MATERIALS AND METHODOLOGY..... | | 40 |
| 3.1 | Cell Culture and drug treatment | 41 |
| 3.2 | Reagents and antibodies..... | 42 |
| 3.3 | Docking and molecular dynamic simulation | 42 |
| 3.4 | Cell transfection..... | 44 |
| 3.5 | Immunocytochemistry (ICC) | 44 |
| 3.6 | Western blotting | 45 |
| 3.7 | HDAC6 deacetylase assay | 45 |
| 3.8 | Quantitative real-time PCR | 46 |
| 3.9 | Immunoprecipitation (IP) | 46 |
| 3.10 | HSP90-ATP binding Assay | 47 |
| 3.11 | Animals and treatment..... | 47 |
| 3.12 | Instruments and analytical conditions..... | 49 |
| 3.13 | Rotarod test..... | 49 |
| 3.14 | Contextual fear conditioning (CFC) test..... | 49 |
| 3.15 | Morris water maze test..... | 50 |
| 3.16 | Immunohistochemistry (IHC)..... | 51 |

| | | |
|--|---|-----------|
| 3.17 | Tau extraction..... | 51 |
| 3.18 | Golgi staining for dendritic spine density | 52 |
| 3.19 | Structural modification of Protopine..... | 53 |
| 3.20 | Characterization of Protopine-Br | 54 |
| 3.20.1 | Mass spectrometry analysis..... | 55 |
| 3.20.2 | Nuclear magnetic resonance spectroscopy | 55 |
| 3.21 | Statistical analysis..... | 55 |
| CHAPTER 4: PROTOPINE PROMOTES THE DEGRADATION OF TAU THROUGH THE INHIBITION OF HDAC6 IN VITRO | | 56 |
| 4.1 | Introduction | 57 |
| 4.2 | Results..... | 58 |
| 4.2.1 | Protopine promotes the degradation of tau <i>in vitro</i> | 58 |
| 4.2.2 | Protopine binds to and inhibits HDAC6 activity..... | 60 |
| 4.2.3 | Protopine inhibits HDAC6 in primary cortical neurons and neuronal cell-lines. | 64 |
| 4.2.4 | HDAC6 overexpression blocks Protopine-mediated degradation of tau | 67 |
| 4.2.5 | Protopine promotes degradation of aggregated tau via the proteasomal system <i>in vitro</i> | 68 |
| 4.2.6 | Protopine promotes ubiquitination of tau <i>in vitro</i> | 70 |
| 4.2.7 | Protopine inhibits HDAC6-HSP90 interaction..... | 72 |
| 4.2.8 | Protopine modulates the chaperone function of HSP90 independent of ATP-binding..... | 74 |
| 4.2.9 | Protopine activates molecular chaperones for the degradation of tau <i>in vitro</i> | 75 |

| | | |
|---|---|------------|
| 4.3 | Discussion..... | 76 |
| | | |
| CHAPTER 5: PROTOPINE ALLEVIATED TAU PATHOLOGY AND IMPROVED COGNITIVE FUNCTIONS IN ALZHEIMER'S DISEASE MICE MODELS..... | | 79 |
| 5.1 | Introduction..... | 80 |
| 5.2 | Results..... | 81 |
| 5.2.1 | Pharmacokinetic and safety profiles of Protopine..... | 81 |
| 5.2.2 | Protopine alleviates cognitive impairment in AD mice models..... | 83 |
| 5.2.3 | Protopine promotes spine formation in the 3xTg-AD mice model..... | 86 |
| 5.2.4 | Protopine reduces hyperphosphorylated tau in AD mice models..... | 87 |
| 5.2.5 | Protopine activates molecular chaperones for the degradation of tau <i>in vivo</i> | 92 |
| 5.2.6 | Protopine activates CHIP E3 ubiquitin ligase <i>in vitro</i> and <i>in vivo</i> | 96 |
| 5.3 | Discussion..... | 98 |
| | | |
| CHAPTER 6: STRUCTURAL MODIFICATIONS OF PROTOPINE FOR ENHANCED BIOAVAILABILITY..... | | 102 |
| 6.1 | Introduction..... | 103 |
| 6.2 | Results..... | 104 |
| 6.2.1 | Characterization of Protopine-Br | 104 |
| 6.2.2 | Pharmacokinetic profile of Protopine-Br | 107 |
| 6.2.3 | Protopine-Br alleviates cognitive impairment in AD mice models. | 108 |
| 6.2.4 | Protopine promotes spine formation in the 3xTg-AD mice model..... | 111 |
| 6.2.5 | Protopine-Br reduces hyperphosphorylated tau in AD mice models. | 112 |
| 6.2.6 | Protopine-Br binds to HDAC6 and inhibits its activity..... | 118 |
| 6.2.7 | Protopine-Br promoted chaperone-mediated pathological tau clearance. | 119 |

| | | |
|---|---|------------|
| 6.3 | Discussion..... | 122 |
| CHAPTER 7: DISCUSSION AND LIMITATION AND CONCLUSION..... | | 124 |
| 7.1 | Activation of UPS is beneficial for AD therapy..... | 125 |
| 7.2 | Protopine and Protopine-Br are promising medicaments for AD therapy.. | 125 |
| 7.3 | Limitations and future study plan. | 125 |
| REFERENCES..... | | 128 |
| PUBLICATION LIST..... | | 171 |
| CURRICULUM VITAE..... | | 176 |

LIST OF FIGURES

| | | |
|------------|--|----|
| Figure 1-1 | Enzymatic cleavage of APP. | 4 |
| Figure 1-2 | Tau protein spliced products. | 6 |
| Figure 1-3 | Tau protein in healthy and Alzheimer's disease brain. | 8 |
| Figure 1-4 | UPS-mediated degradation of cellular proteins. | 12 |
| Figure 1-5 | Major tau degradation mechanisms. | 15 |
| Figure 1-6 | Balance between HAT and HDAC for maintenance of neuronal homeostasis. | 19 |
| Figure 1-7 | Various tau modulators in preclinical and clinical trials of AD. | 23 |
| Figure 1-8 | Herbal combination of Yuanhu Zhi Tong (YZT 元胡止痛). | 25 |
| Figure 3-1 | Classes of dendritic spines | 53 |
| Figure 3-2 | Synthesis of protopine derivatives. | 54 |
| Figure 4-1 | Protopine promotes degradation of tau <i>in vitro</i> . | 59 |
| Figure 4-2 | Protopine inhibits HDAC6 activity. | 62 |
| Figure 4-3 | Protopine can bind to HDAC6 <i>in vitro</i> and <i>in silico</i> . | 63 |
| Figure 4-4 | Protopine inhibits HDAC6 in a dose- and time-dependent manner in primary cortical neurons. | 65 |
| Figure 4-5 | Protopine inhibits HDAC6 in a dose- and time-dependent manner <i>in vitro</i> . | 66 |
| Figure 4-6 | HDAC6 overexpression blocks Protopine-mediated degradation of pathological tau | 68 |
| Figure 4-7 | Protopine promotes UPS-mediated degradation of tau <i>in vitro</i> . | 69 |
| Figure 4-8 | Protopine promotes ubiquitination of tau <i>in vitro</i> . | 72 |

| | | |
|-------------|--|-----|
| Figure 4-9 | Protopine impairs HDAC6-HSP90 interaction <i>in vitro</i> . | 73 |
| Figure 4-10 | Protopine does not affect ATP binding to HSP90. | 75 |
| Figure 4-11 | Protopine enhances the expression of molecular chaperones <i>in vitro</i> . | 76 |
| Figure 5-1 | Safety profile of Protopine <i>in vivo</i> . | 82 |
| Figure 5-2 | Protopine reversed the cognitive impairment in the 3xTg-AD mice model. | 84 |
| Figure 5-3 | Protopine enhances motor and learning behavior in the P301S tau mice model. | 86 |
| Figure 5-4 | Protopine can improve synaptic spine density in the 3xTg-AD mice model. | 87 |
| Figure 5-5 | Protopine does not influence APP cleavage in the 3xTg-AD mice model. | 88 |
| Figure 5-6 | Protopine decreased insoluble tau aggregates in 3xTg-AD mice model. | 90 |
| Figure 5-7 | Protopine can reduce pathological tau in the P301S mice model. | 91 |
| Figure 5-8 | Impairment of molecular chaperones in the P301S mice model. | 93 |
| Figure 5-9 | Protopine enhances the expression of molecular chaperones <i>in vivo</i> . | 96 |
| Figure 5-10 | Protopine enhances the expression of CHIP <i>in vitro</i> and <i>in vivo</i> . | 98 |
| Figure 6-1 | Synthesis of protopine derivative Protopine-Br (PRO-Br). | 105 |
| Figure 6-2 | Physical and chemical characterization of Protopine-Br. | 107 |
| Figure 6-3 | Pharmacokinetic profile of Protopine-Br <i>in vivo</i> . | 108 |
| Figure 6-4 | Protopine-Br promotes degradation of tau <i>in vitro</i> . | 109 |
| Figure 6-5 | Protopine-Br rescues 3xTg-AD mice from cognitive impairment. | 110 |
| Figure 6-6 | Protopine-Br rescues P301S tau mice from cognitive impairment | 111 |
| Figure 6-7 | Protopine-Br can improve dendritic spine density in the 3xTg-AD mice model. | 112 |
| Figure 6-8 | Protopine-Br reduced the insoluble phospho-tau in AD mice | |

| | |
|--|-----|
| models. | 116 |
| Figure 6-9 Protopine-Br reduced the insoluble tau aggregates in AD mice | |
| models. | 117 |
| Figure 6-10 Protopine-Br specifically binds to HDAC6. | 119 |
| Figure 6-11 Protopine-Br enhanced molecular chaperones for the degradation | |
| of pathological tau <i>in vitro</i> and <i>in vivo</i> . | 121 |

LIST OF TABLES

| | | |
|-----------|---|-----|
| Table 1-1 | List of selective bioactive components in Rhizoma Corydalis. | 31 |
| Table 1-2 | List of selective bioactive components in Radix Angelicae Dahuricae | 35 |
| Table 3-1 | Synthesis of protopine derivatives. | 54 |
| Table 4-1 | Protopine can bind to HDAC6 <i>in vitro</i> and <i>in silico</i> . | 63 |
| Table 5-1 | Pharmacokinetic profile of Protopine in mice brain and plasma. | 82 |
| Table 6-1 | Pharmacokinetic profile of Protopine-Br in mice brain and plasma. | 108 |
| Table 6-2 | Protopine-Br specifically binds to HDAC6. | 119 |